Wright, Eugene E.

Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease

Kanwal, F., Shubrook, J. H., Adams, L. A., Pfotenhauer, K., Wai-Sun Wong, V., Wright, E., Abdelmalek, M. F., Harrison, S. A., Loomba, R., Mantzoros, C. S., et al. (2021) · Gastroenterology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 618

Oxidative stress in type 2 diabetes: the role of fasting and postprandial glycaemia

Wright, E., Scism-Bacon, J. L., & Glass, L. C. (2006) · International Journal of Clinical Practice

Advanced Glycation End Products researchNitric Oxide and Endothelin Effects

Cited by 517

A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings

Klonoff, D. C., Wang, J., Rodbard, D., Kohn, M. A., Li, C., Liepmann, D., Kerr, D., Ahn, D., Peters, A. L., Umpierrez, G. E., et al. (2023) · Journal of Diabetes Science and Technology

Diabetes Management and ResearchDiabetes Management and Education

Cited by 295

The evolution of insulin and how it informs therapy and treatment choices

Hirsch, I. B., Juneja, R., Beals, J. M., Antalis, C. J., & Wright, E. E. (2020) · Endocrine Reviews

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 237

Use of Flash Continuous Glucose Monitoring Is Associated With A1C Reduction in People With Type 2 Diabetes Treated With Basal Insulin or Noninsulin Therapy

Wright, E. E., Kerr, M. S. D., Reyes, I. J., Nabutovsky, Y., & Miller, E. (2021) · Diabetes Spectrum

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 115

Glucagon‐like peptide‐1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta‐analysis

Singh, S., Wright, E. E., Kwan, A. Y. M., Thompson, J. C., Syed, I. A., Korol, E. E., Waser, N. A., Yu, M. B., & Juneja, R. (2017) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 101

Time in range: How to measure it, how to report it, and its practical application in clinical decision-making

Wright, E. E., Morgan, K., Fu, D. K., Wilkins, N., & Guffey, W. J. (2020) · Clinical Diabetes

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 40

84-LB: HbA1c Reduction after Initiation of the FreeStyle Libre System in Type 2 Diabetes Patients on Long-Acting Insulin or Noninsulin Therapy

MILLER, E., BRANDNER, L., & WRIGHT, E. (2020) · Diabetes

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 23

Initiating GLP-1 Therapy in Combination with FreeStyle Libre Provides Greater Benefit Compared with GLP-1 Therapy Alone

Wright, E. E., Roberts, G. J., Chuang, J. S., Nabutovsky, Y., Virdi, N., & Miller, E. (2024) · Diabetes Technology & Therapeutics

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 22

Association of Changes in A1C Following Continuous Glucose Monitoring Acquisition in People with Sub-Optimally Treated Type 2 Diabetes Taking GLP-1 RA Therapy

Miller, E., Chuang, J. S., Roberts, G. J., Nabutovsky, Y., Virdi, N., & Wright, E. E. (2024) · Diabetes Therapy

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 9